Lung

• (106-16) A Pilot Multi-Arm Study of sEphB4-HSA In Combination with Different Chemotherapy Regimens in Patients with Specific Advanced or Metastatic Solid Tumors (Phase 1 clinical trial, appropriate for patients with metastatic cancers of the bile duct, gallbladder; head and neck; non-small cell lung; and pancreas.)

• (109-17) A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung) (Phase 2 clinical trial, appropriate for patients with lung cancer.)

• (110-17) A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Nivolumab in Patients With Unresectable Non-Small Cell Lung Cancer (Phase 1 clinical trial, appropriate for patients with non-small cell lung cancer.)

• (131-17) A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers (Phase 1 clinical trial, appropriate for patients with solid tumors.)

• (134-17) A Phase IIa trial of sEphB4-HSA in combination with Anti PD-1 Antibody (Pembrolizumab, MK-3475) in patients with non-small cell lung and head/neck cancer (Phase 2 clinical trial, appropriate for patients with lung, head or neck cancer.)

• (151-17) A Phase 1, Open-Label, Dose Escalation Study of Pf-04518600 as a Single Agent and In Combination with PF-05082566 In Patients with Selected Locally Advanced or Metastatic Carcinomas (Phase 1 clinical trial, appropriate for patients with locally advanced or metastatic carcinomas of the lung.)

• (155-17) 0C 17-1: Phase 1 Multi-center Study of the Safety Pharmacokinetics and Preliminary Efficacy of CBT-101 in Subjects with Advanced Solid Tumors and C-Met Dysregulation (Phase 1 clinical trial, appropriate for patients with advanced solid malignancies.)

• (157-17) FID-007 in Treating Participants With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid malignancies.)

• (167-17) Caris ctDNA Validation Project (Research study, appropriate for patients with all solid tumors.)

• (179-17) Pilot program to assess the potential role of pharmacogenomics to improve drug safety in patients with advanced cancer. (Clinical research study, appropriate for patients with brain, breast, GI, lung or ovarian cancer.)

• (187-17) Phase 1 trial of ZW25 in patients with locally advanced (unresectable) and/or metastatic HER2-expressing cancers (Phase 1 clinical trial, appropriate for patients with HER2 expressing cancers.)

• (208-17) A multicenter, open-label, phase 1b/2 study to evaluate safety and efficacy of avelumab (MSB0010718C) in combination with chemotherapy with or without other anti-cancer immunotherapies as first-line treatment in patients with advanced malignancies (Phase 1b/2 clinical trial, appropriate for patients with bladder and lung cancers.)

• (211-17) Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)

• (214-17) A Phase 1/2 First-in-human Study of BMS-986258 Alone and in Combination with Nivolumab in Advanced Malignant Tumors (Phase 1/2 clinical trial, appropriate for patients with advanced malignant tumors.)